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In chronic infection and cancer, T cells acquire a
dysfunctional state characterized by the expression
of inhibitory receptors. In vitro studies implicated
the phosphatase Shp-2 downstream of these recep-
tors, including PD-1. However, whether Shp-2 is
responsible in vivo for such dysfunctional responses
remains elusive. To address this, we generated
T cell-specific Shp-2-deficient mice. These mice did
not show differences in controlling chronic viral in-
fections. In this context, Shp-2-deleted CD8+ T lym-
phocytes expanded moderately better but were
less polyfunctional than control cells. Mice with
Shp-2-deficient T cells also showed no significant
improvement in controlling immunogenic tumors
and responded similarly to controls to a-PD-1 treat-
ment. We therefore showed that Shp-2 is dispens-
able in T cells for globally establishing exhaustion
and for PD-1 signaling in vivo. These results reveal
the existence of redundant mechanisms down-
stream of inhibitory receptors and represent the
foundation for defining these relevant molecular
events.
INTRODUCTION
Chronic antigen exposure drives T cell exhaustion, a condition in
which effector T cells progressively lose the capacity to produce
multiple cytokines and proliferate (Pauken and Wherry, 2015).
This phenomenon represents an adapted response reducing
excessive T cell activation and collateral damage, but it also
hampers immunity (Speiser et al., 2014). Exhausted T cells are
characterized by the expression of inhibitory receptors, including
programmed cell death 1 (PD-1). Blocking signaling by PD-1 and
other inhibitory receptors restores T cell responses, effectively
promoting disease control in cancer patients (Pauken andThis is an open access article under the CC BY-NWherry, 2015; Topalian et al., 2015). These findings reveal
the potential of interfering with such inhibitory circuits and the
need to understand the underlying molecular pathways.
Cytoplasmic tails of inhibitory receptors bear immunoreceptor
tyrosine-based inhibition motifs (ITIMs) and immunoreceptor
tyrosine-based switchmotifs (ITSMs), which are phosphorylated
upon engagement and act as docking sites for SH2 domain-con-
taining protein tyrosine phosphatase (Shp)-2 (encoded by the
Ptpn11 gene) and the homologous Shp-1 (Siminovitch and
Neel, 1998; Tajan et al., 2015). These phosphatases contain
SH2 domains that interact with phosphotyrosines of receptors
or signaling molecules, favoring accessibility of the catalytic
site (Cunnick et al., 2001; Ekman et al., 2002; Noguchi et al.,
1994; Siminovitch and Neel, 1998). Opposite to Shp-1, which
dampens various signaling cascades, Shp-2 is mainly known
for positively regulating growth factor or hormone receptor
signaling, and its activity has been implicated in several malig-
nancies (Chan et al., 2008; Prahallad et al., 2015; Tajan et al.,
2015; Zhang et al., 2015).
Although several mousemodels expressing a dominant-nega-
tive form of or lacking Shp-2 in T cells have been reported (Dong
et al., 2015; Liu et al., 2017;Miah et al., 2017; Nguyen et al., 2006;
Salmond et al., 2005; Zhang et al., 2013), a consensus on its role
in these lymphocytes is missing. Some models showed defec-
tive T cell development and/or activation, whereas others ex-
hibited normal T cells with unaltered or enhanced responses
(Dong et al., 2015; Kwon et al., 2005; Liu et al., 2017; Miah
et al., 2017; Nguyen et al., 2006; Salmond et al., 2005). In agree-
ment with its known contribution to the mitogen-activated
protein kinase (MAPK) pathway in cancerous cells and various
tissues, multiple studies observed a positive role for Shp-2
in extracellular signal-regulated kinase (ERK) activation upon
T cell receptor (TCR) triggering or interleukin (IL)-2 stimulation
(Gadina et al., 1998; Kwon et al., 2005; Nguyen et al., 2006;
Salmond et al., 2005).
In relation to T cell exhaustion, in vitro studies showed recruit-
ment of Shp-2 to the cytoplasmic portion of PD-1 and other
inhibitory receptors (Chemnitz et al., 2004; Hui et al., 2017;
Latchman et al., 2001; Lee et al., 1998; Okazaki et al., 2001;Cell Reports 23, 39–49, April 3, 2018 ª 2018 The Authors. 39
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. CD4cre Ptpn11fl/fl Mice Exhibit Normal T Cells
(A–C) Thymus cellularity (A) and percentage of double-negative (DN) thymocytes (CD4CD8), double-positive (DP) thymocytes (CD4+CD8+), and CD4 or CD8
single-positive (SP) thymocytes (CD4+CD8 or CD4CD8+, respectively) among lineage-negative lymphocytes (B) are depicted in CD4cre Ptpn11wt/wt, CD4cre
Ptpn11fl/fl, and Ptpn11fl/fl mice. (C) Representative flow cytometry plots of CD4 and CD8 expression among lineage-negative thymocytes are illustrated. (A–C)
Data are comparable in mice of 6 to 12 weeks.
(D) Spleen cellularity and percentages of CD4+ (CD4+ CD3+) and CD8+ (CD8+ CD3+) T cells (gated on lymphocytes) are illustrated.
(E and F) Percentages of naive (CD44low-int CD62Lhigh), CM-like (CD44high CD62Lhigh), and EM-like (CD44high CD62Llow) CD4+ and CD8+ T lymphocytes in the
spleen (E) and a representative flow cytometry plot of CD62L and CD44 expression (F) are depicted.
Results represent mean ± SEM of n = 3–5 mice/group (A, B, D, and E) and are representative of at least two independent experiments (A–F). Only statistically
significant differences are shown. **p% 0.01; Student’s t test. See also Figure S1.Peled et al., 2018; Sheppard et al., 2004; Yamamoto et al., 2008;
Yokosuka et al., 2012). Furthermore, a negative effect of Shp-2
on IL-2 production has been observed upon PD-1 engagement
(Peled et al., 2018; Yokosuka et al., 2012). Shp-2 is therefore
considered a central molecule for T cell exhaustion and one to
target for therapeutic purposes. Yet work addressing its role in
the context of chronic antigen exposure in vivo is missing. We
therefore generatedCD4cre Ptpn11fl/flmice and tested the effect
of Shp-2 ablation on T cell responses.
Following chronic viral infection, we found increased percent-
ages of antiviral Ptpn11-deficient T cells compared to control
mice. However, these cells exhibited compromised cytokine
production and were unable to better control the infection. In
addition, we subcutaneously engrafted mice with an immuno-
genic cancer. Tumor growth inCD4cre Ptpn11fl/flmice was com-
parable to what was observed in controls, and these mice re-
sponded to a-PD-1 treatment. Therefore, Shp-2 deficiency in
T cells does not ameliorate disease outcome and—against the40 Cell Reports 23, 39–49, April 3, 2018commonly held view—does not impede PD-1 signaling, urging
investigation of alternative molecular players.
RESULTS
CD4cre Ptpn11fl/fl Mice Present a Normal T Cell
Compartment
First,wecharacterized the T cell compartment ofCD4crePtpn11fl/
flmiceascompared toCD4crePtpn11wt/wtandPtpn11fl/flcontrols.
As expected, Ptpn11 transcript and protein expressionwere lack-
ing in T cell fractions from CD4cre Ptpn11fl/fl mice ex vivo and
following in vitro activation (Figures S1A and S1B). Furthermore,
expression of Shp-1 was unaltered, underlying the specificity of
Shp-2 deletion (Figures S1A and S1B).
With regard to thymic development,CD4crePtpn11fl/flmicedid
not exhibit differences in thymus cellularity, frequency of CD8 and
CD4 double-positive populations, or frequency of single-positive
subpopulations (Figures 1A–1C). To exclude that differences in
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Figure 2. Percentages of Ptpn11-Deleted CD8+ T Cells Are Increased upon Chronic Infection
(A) Graphs illustrate percentages of CD8+ T cells at days 8 and 20 p.i. in the blood and percentages and numbers at day 34 p.i. in the spleen ofCD4cre Ptpn11wt/wt,
CD4cre Ptpn11fl/fl, or Ptpn11fl/fl mice.
(B and C) Graphs illustrate percentages (among lymphocytes) and numbers of CD44high CD62Llow effector (B) or PD-1+ (C) CD8+ T cells.
(D and E) Graphs illustrate percentages (among lymphocytes) and numbers of gp33-specific (gp33+) (D) and gp276-specific (gp276+) (E) CD8+ T cells.
(legend continued on next page)
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signaling were compensated for by an altered TCR repertoire, we
analyzed thymic development in P14 transgenicmice, which bear
a TCR specific for the lymphocytic choriomeningitis virus (LCMV)
glycoprotein (gp) 33, and found normal thymic cellularity and fre-
quency of thymocyte subsets (Figures S1C and S1D). In addition,
we observed unaltered expression of CD5, CD24, and CD69 and
of TCR Va2 and b chains on double-positive and CD8 single-pos-
itive thymocytes (Figures S1E and S1F). Altogether, these results
indicate that T cells from CD4cre Ptpn11fl/flmice undergo normal
thymic selection.
We next analyzed the peripheral T cell compartment in both
spleen and inguinal lymph node. In the spleen, we observed no
major differences in the percentages of CD4+ and CD8+
T cells, besides a mild tendency toward increased CD8+
T cells (Figure 1D). Furthermore, the activation state of T lympho-
cytes, as measured by CD44 and CD62L expression, was unaf-
fected (Figures 1E and 1F). Similar results were obtained for
inguinal lymph nodes (Figures S1G–S1I). Altogether, these data
indicate that Shp-2 is dispensable for T cell homeostasis in
CD4cre Ptpn11fl/fl mice.
Ablation of Shp-2 Increases the Frequency of T Cells
Specific for Chronic LCMV
With this premise, we challenged mice with LCMV clone 13,
which establishes a chronic infection and is therefore widely
used as model to study T cell exhaustion. Percentages of
Ptpn11-deficient CD8+ T cells were similar to controls early after
infection (day 8 post-infection [p.i.]) but increased in the chronic
phase of the disease (days 20 and 34 p.i.) (Figure 2A). No consis-
tent alterations were observed among CD4+ T cells (Figures S2A
and S2B).
We next asked whether the increase of CD8+ T cell percent-
ages in the chronic phase of LCMV infection affected these lym-
phocytes globally or a particular subset. As shown in Figure 2B,
the CD44high CD62Llow effector subpopulation, which roughly
corresponded to PD-1+ T cells, was augmented in CD4cre
Ptpn11fl/fl mice (Figure 2C; Figure S2C). In agreement, CD8+
T cells specific for gp33 and gp276 showed normal expansion
early after infection and were more abundant in CD4cre
Ptpn11fl/fl mice at later time points, albeit to different extents
(Figures 2D–2G). However, CD4cre Ptpn11fl/fl mice had spleens
of tendentially reducedcellularity following infection (FigureS2D),
rendering the numbers of antiviral CD8+ T cells in CD4cre
Ptpn11fl/fl mice not increased compared to controls (Figures
2A–2E). T cells bearing only one functional Ptpn11 allele, from
CD4cre Ptpn11wt/fl mice, behaved comparably to control cells
(Figure S2E). Altogether, these data indicate thatPtpn11 deletion
favored increased frequencies of antiviral T cells.
Shp-2 Limits the Expansion of Exhausted CD8+ T Cells
To gain further insight into the mechanisms leading to increased
percentages of Ptpn11-deleted effector CD8+ T cells, we took(F andG) Representative flow cytometry plots (gated onCD8+ T cells), asmeasure
(F) or gp276-specific (G) CD8+ T cells.
Results represent mean ± SEM of n = 6–15 mice/group (A–D) or n = 5–8 mice/gro
least three experiments (A–D and F) or two experiments (E and G). Only difference
**p% 0.01, ***p% 0.001; Student’s t test. See also Figure S2.
42 Cell Reports 23, 39–49, April 3, 2018advantage of P14 transgenic T cells. After adoptive cotransfer
of Ptpn11-deficient and control P14 CD8+ T cells (Figure 3A),
we infected recipient mice with LCMV clone 13. Although per-
centages of Ptpn11-deficient and control P14 CD8+ T cells
were comparable at day 8 p.i., the former became on average
2.9 timesmore abundant than the latter during the chronic phase
of infection (Figures 3A and 3B). These results proved that
accumulation of Ptpn11-deficient CD8+ T cells is a cell-intrinsic
phenomenon, independent of viral load and thymic output.
The subpopulations of T cells expressing high T-bet and
low Eomesodermin levels or the transcription factor Tcf-1 have
been shown to renew and sustain the persistent antiviral
response (Im et al., 2016; Paley et al., 2012; Utzschneider
et al., 2016). However, their frequencies among Ptpn11-deficient
P14 CD8+ T cells were either unaltered or decreased following
chronic infection, while they were high upon acute LCMV infec-
tion, irrespectively of the genotype (Figures 3C–3F). These
results suggest that the above mechanisms are not responsible
for the observed phenotype. We recurrently observed
an increased proportion of Ki67+ proliferating cells among
Ptpn11-deficient P14 T cells (Figures 3G and 3H), indicating
that Shp-2 hampered the proliferative capacity of exhausted
T cells.
However, expansion of antiviral Pdcd1-deficient T cells has
been reported to be greater and occur with faster kinetics (Odor-
izzi et al., 2015). Underlining the divergence in the roles of PD-1
and Shp-2 in exhausted CD8+ T cells, we observed that Pdcd1-
deficient P14CD8+ T cells expanded significantly more than their
Ptpn11-deficient counterparts 11 days after chronic LCMV infec-
tion (Figure S3A).
Shp-2 Sustains Polyfunctional CD8+ T Cells in Chronic
LCMV Infection
We next asked whether Ptpn11-deficient P14 CD8+ T cells from
LCMV clone 13-infected mice presented classical exhaustion
features. Compared to CD8+ T cells exposed to acute infection,
they displayed high levels of inhibitory receptors (Figure 4A).
However, while the levels PD-1, lymphocyte-activation gene 3
(Lag3), and T cell immunoreceptor with immunoglobulin (Ig)
and ITIM domains (Tigit) were comparable to those of control
cells, expression of 2B4 was lower (Figure 4A).
Furthermore, we investigated cytokine production. Because
Shp-2 has been implicated in TCR and costimulation or coinhibi-
tion signaling (Lee et al., 1998), we restimulated Ptpn11-deficient
P14 CD8+ T cells with a-CD3 or a-CD3/CD28, enabling control of
the engagement of these pathways at the synapse. Although we
observed normal degranulation (Figures 4B and 4C) and inter-
feron gamma (IFN-g) production, IFN-g/tumor necrosis factor
alpha (TNF-a) double-producer cells were underrepresented
(Figures 4D and 4E). Similar results were observed upon restim-
ulation with gp33 peptide (Figures S4A–S4D). Concomitant re-
stimulation of P14 T cells from mice infected with acute LCMVd in the blood at days 8 and 20 p.i. or in the spleen at day 34 p.i. of gp33-specific
up (E) are a pool of two independent experiments and are representative of at
s statistically significant in comparison to both controls are shown. *p% 0.05,
AC
E
G H
F
D
B
Figure 3. Ptpn11-Deficient T Cells Are Increased upon Chronic Infection
Wild-type recipient mice were cotransferred with a 1:1 mix of congenically marked control (which, depending on the experiment, is on a CD4cre Ptpn11wt/wt,
CD4cre Ptpn11wt/fl, or Ptpn11fl/fl background) and Ptpn11-deficient (knockout [KO]) (CD4cre Ptpn11fl/fl background) P14 CD8+ T cells and infected with LCMV
clone 13.
(A) Percentages of KO (CD45.1/2) and control (CD45.1) P14 T cells in the initial mix, in the blood at the indicated days, and in the spleen at day 31 p.i. are shown as
representative flow cytometry plots (gated on CD8+ CD45.1+ T cells).
(B) Graph depicts the ratio, normalized to the initial mix, of KO over control P14 T cells at days 7–10 and 31–35 and representsmean ±SEMof the average value of
five independent experiments.
(C–F) Representative flow cytometry plots and graphs depict the percentage of T-bet-high and Eomesodermin-low (T-bethiEomeslow) (C and D) and of Tcf-1
positive (Tcf-1+) (E and F) KO and control P14 T cells 29 days after infection with LCMV clone 13 or Armstrong.
(legend continued on next page)
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further evidenced the dysfunctional state of cells from LCMV
clone 13-infected animals (Figures S4C and S4D).
Because IL-2 production severely declines upon chronic
infection, we tested it following gp33 restimulation at 9 and
29 days p.i. Both control and Ptpn11-deficient CD8+ T cells
from chronically infected mice produced little IL-2, with the latter
synthetizing tendentially lower amounts (Figures 4F and 4G).
Altogether, Shp-2-deficient T cells exhibited severe dysfunc-
tional features.
To outline the overall effect of Shp-2 deletion in T cells, we
measured viral titers longitudinally in serum and at day 34 p.i.
in the kidney of CD4cre Ptpn11fl/fl and control mice. At all tested
time points, we observed comparable virus levels in mice of the
different genotypes (Figures S4E and S4F), indicating that the ef-
fects of Ptpn11 deficiency in T cells are not sufficient to substan-
tially alter viral control.
CD4cre Ptpn11fl/fl Mice Show Normal Anticancer
Responses and Therapeutic Effects by PD-1 Blockade
Because the antitumoral T cell response is characterized by
exhaustion and its modulation is highly relevant for immuno-
therapy, we investigated the role of Shp-2 in T cells and the
combination with a-PD-1 treatment in this context. We chose
the immunogenic MC38 adenocarcinoma, which is robustly
controlled in Pdcd1-deficient mice (Figure S5A) (Juneja et al.,
2017). We subcutaneously engrafted CD4cre Ptpn11fl/fl and
control mice with tumor cells. When the tumor was palpable,
mice were divided into two groups; one was then injected three
times with a-PD-1 antibody, and the other received three injec-
tions of isotype control. CD4cre Ptpn11fl/fl and control mice
presented comparable tumor volumes at this stage (Fig-
ure S5B). After 30 days, all isotype-treated mice developed
large lesions (Figure 5A). To further assess whether alterations
in CD4+ T cells indirectly modulated CD8+ T cell anticancer ac-
tivity in CD4cre Ptpn11fl/fl mice, we depleted them. This hin-
dered tumor growth in both control and CD4cre Ptpn11fl/fl
mice (Figure S5C) (Yu et al., 2005), indicating that antitumoral
CD8+ T cell responses were not inherently different. We thus
tested the effects of a-PD-1 treatment. This improved tumor
control and mouse survival irrespective of the genotype
analyzed, in some cases leading to complete remission (Figures
5B and 5C).
To evaluate whether a-PD-1 treatment exerted the expected
effects on intratumoral CD8+ T cells, we examined mice
12 days after engraftment, when therapy started to show effi-
cacy but before numerous tumors were eradicated (Figure S5D).
With respect to isotype-treatedmice, we detected no substantial
differences linked to Ptpn11 deletion in the frequency of tumor-
infiltrating T lymphocytes (Figures 5D; Figure S5E). Furthermore,
the proportions of IFN-g+, PD-1+, 2B4+, and Lag3+ among infil-
trating CD8+ T cells were comparable in CD4cre Ptpn11fl/fl and
control mice (Figure 5E; Figure S5F).(G and H) A histogram illustrates Ki67 staining of splenic KO and control P14 T c
Data illustrate mean ±SEMof n = 3mice/group (Armstrong) (D), and n = 6mice/gro
three (A), two (C–F), and three out of five (G and H) independent experiments. On
Student’s t test (B) and Student’s t test (D, F, and H). See also Figure S3.
44 Cell Reports 23, 39–49, April 3, 2018a-PD-1 treatment increased the percentages of total and IFN-
g-expressing intratumoral CD8+ T cells in bothCD4cre Ptpn11fl/fl
and control mice but reached significance only in the former
(Figures 5D and 5E). The efficacy of PD-1 blockade in CD4cre
Ptpn11fl/fl mice revealed that Shp-2 is dispensable for PD-1
signaling in exhausted T cells, indicating that additional players
are engaged.
DISCUSSION
Here we addressed the relevance of Shp-2 in exhausted T cells
by studyingCD4cre Ptpn11fl/flmice. In agreement with published
studies, we observed that T cells are normal in the absence of
Shp-2 (Dong et al., 2015; Liu et al., 2017), rendering these
mice suitable for further analyses.
Cotransfer experiments of control and Ptpn11-deficient T cells
into wild-type mice uncovered enhanced expansion of the latter
following chronic viral infection. In agreement, CD4cre Ptpn11fl/fl
mice exhibited increased percentages of virus-specific cytotoxic
T cells compared to their control counterparts but no reduction
in viral titers. This could be explained by the observation that
antiviral T cells were not numerically augmented and exhibited
an altered clonal representation, as indicated by the exaggerate
proportion of gp33-specific T cells late in the infection. More-
over, we measured decreased frequency of polyfunctional
Ptpn11-deficient T cells, which are important for viral control.
Along these lines, our results suggested no or a rather positive
role for Shp-2 on IL-2 production in the late phase of the infec-
tion. However, in vitro experiments showed that secretion of
this cytokine was suppressed by Shp-2 upon concomitant
TCR and PD-1 engagement (Peled et al., 2018; Yokosuka
et al., 2012). One limitation of in vivo approaches is that these
do not enable dissecting the effects of Shp-2 and the pathways
in which it operates with the same temporal and molecular accu-
racy as in in vitro settings. However, they answer the central
question on the role of this phosphatase in exhausted T cells.
In clinically relevant contexts, we thus showed that Shp-2 does
not substantially control T cell exhaustion.
The characteristics of Ptpn11-deficient T cells differ from
those of PD-1 deletion. T cells lacking PD-1 present massive
proliferation early after LCMV clone 13 infection, causing exces-
sive immunopathology and mortality of infected mice (Barber
et al., 2006; Frebel et al., 2012; Odorizzi et al., 2015); this was
not the case for Ptpn11-deficient T cells. Furthermore, whereas
Pdcd1-deficient mice effectively control the immunogenic tu-
mors MC38 and B16, CD4cre Ptpn11fl/fl mice succumbed with
the same kinetics as wild-type controls (Juneja et al., 2017;
Woo et al., 2012; Zhang et al., 2013).
Because the role of Shp-2 in regulating PD-1 signaling might
have been confounded by additional pathways involving this
phosphatase, we tested the response of CD4cre Ptpn11fl/fl
mice to PD-1 blockade. The effects of a-PD-1 treatment wereells at day 31 p.i. (G) and a quantification thereof (H).
up (clone 13) (F), and n = 7mice/group (H). Results are representative of at least
ly statistically significant differences are shown. *p% 0.05, **p% 0.01; paired
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Figure 4. Ptpn11-Deficient T Cells Are Dysfunctional upon Chronic Infection
Wild-type recipient mice were cotransferred with a 1:1 mix of congenically marked control and Ptpn11-deficient P14 CD8+ T cells and infected with LCMV
clone 13.
(A) Graphs depict the geometric mean fluorescence intensity (MFI) of PD-1, Lag3, 2B4, and Tigit on control and Ptpn11-deficient P14 CD8+ T cells 29 days
following infection with LCMV clone 13 or Armstrong.
(B–E) Splenocytes isolated from infected mice at day 31 p.i. were restimulated with a-CD3 or a-CD3/CD28 and stained for CD107a (B and C), IFN-g, and TNF-a
(D and E). Graphs illustrate frequencies of CD107a+ (B), IFN-g+, and TNFa+ among IFN-g+ (D) Ptpn11-deficient and control P14 T cells, and representative flow
cytometry pictures are shown (C and E).
(F and G) Splenocytes from mice infected with LCMV clone 13 or Armstrong at day 9 or 29 p.i. were restimulated with gp33 peptide and stained for IL-2. Graphs
illustrate frequencies of IL-2+ Ptpn11-deficient and control P14 T cells (F), and representative flow cytometry pictures are shown (G).
Results depict mean ± SEM of n = 3 (Armstrong) and n = 6 (clone 13) mice/group (A and F), n = 6 or 7 mice/group (B and D) and are representative of at least two
independent experiments (A–G). Only statistically significant differences are shown. **p% 0.01; Student’s t test (A, B, D, and F). See also Figure S4.
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Figure 5. CD4cre Ptpn11fl/fl Mice Respond to a-PD-1 Treatment
(A–C)Mice of the indicated genotypeswere s.c. inoculated withMC38 cells. (A and B) Tumor growth in individualmice is shown; (A) depictsmice receiving isotype
control injections, while (B) showsmice treated with a-PD-1 antibody. The number of mice eradicating the tumor is indicated within the graphs. (C) Survival curves
from mice treated as in (A) and (B).
(legend continued on next page)
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appreciable, demonstrating that Shp-2 in T cells is dispensable
for PD-1-mediated signaling. Our results are in agreement with
previous in vitro work showing that T cells expressing a domi-
nant-negative form of Shp-2 responded to PD-1 engagement
(Salmond et al., 2005). Given the compelling evidence for
Shp-2 recruitment to PD-1 (Chemnitz et al., 2004; Hui et al.,
2017; Latchman et al., 2001; Lee et al., 1998; Okazaki et al.,
2001; Peled et al., 2018; Sheppard et al., 2004; Yamamoto
et al., 2008; Yokosuka et al., 2012), we propose that redundant
mechanisms mediate this inhibitory signaling. The cytoplasmic
tail of PD-1 is dephosphorylated by Shp-2 as part of a feedback
loop (Hui et al., 2017; Yokosuka et al., 2012). This suggests
accumulation of phosphorylated PD-1 and recruitment of other
phosphatases to be enhanced in the absence of Shp-2.
The development of Shp-2 inhibitors is key to improve the
clinical management of several malignancies (Chen et al.,
2016; Lan et al., 2015). Together with the expanding use of
immunotherapeutic approaches, we felt that a deeper under-
standing of the role of Shp-2 in T cell exhaustion was essential.
While we showed that Shp-2 deletion in T cells failed to provide
an advantage in controlling growth of immunogenic tumors, this
did not hinder the therapeutic effects of PD-1 blockade, support-
ing the prospect of combination therapies.
Despite the increasing use of inhibitory receptor blocking
antibodies in patients, our findings highlight how the engaged
signaling pathways remain poorly understood. We demonstrate
that Shp-2 is dispensable for imprinting the global dysfunctional
state of T cells in vivo. Our results are relevant for translational
research and encourage further investigations that will uncover
novel targets for anticancer therapies.
EXPERIMENTAL PROCEDURES
Additional information on the experimental procedures used is included in the
Supplemental Information.
Mice
Ptpn11fl/fl mice (Grossmann et al., 2009) were on a mixed C57BL/6
background and crossed at least six additional times on C57BL/6 in the
animal facility of the University of Lausanne. CD4cre deleter strain was
from Jackson Laboratory. Ptpn11fl/fl control mice were littermates of CD4cre
Ptpn11fl/fl mice. CD45.1+ P14ab mice (Pircher et al., 1990) on a C57BL/6
background were crossed onto CD4cre Ptpn11fl/fl and onto a Pdcd1-
deficient background (Nishimura et al., 1998) in the animal facility of the
University of Lausanne. Unless otherwise specified, male and female 6- to
12-week-old mice were used in different experiments with appropriate sex-
and age-matched controls.
LCMV Infection
LCMV clone 13 and Armstrong strain were propagated as previously
described (Ludigs et al., 2016). Frozen stocks were diluted in PBS; 23 106 pla-
que-forming units of LCMV (clone 13) were injected intravenously or 2 3 105(D and E) 12 days following MC38 tumor inoculation and the day after the third in
infiltrating T cells were analyzed. Graphs depict percentages of CD8+ (CD8+ CD
cells.
Results depict n = 9–11mice/group (A and B), n = 16–19 mice/group (C), and are a
log-rank (Mantel-Cox) test; isotype-treated CD4cre Ptpn11fl/fl and CD4cre Ptpn11
mice, p = 0.0205; a-PD-1-treated CD4cre Ptpn11fl/fl and CD4cre Ptpn11wt/wt or w
0.2975. (D and E) Results depict mean ± SEM of n = 6-9 mice/group and are a po
0.05; Student’s t test. See also Figure S5.plaque-forming units (Armstrong) were injected intraperitoneally. Transgenic
P14 CD8+ T cells were isolated with a-CD8a magnetic beads (Miltenyi Biotec).
Unless otherwise specified, 2 3 103–4 3 103 control and an equal number of
CD4cre Ptpn11fl/fl P14 CD8+ T cells were intravenously cotransferred into
naive C57BL/6 mice, which were infected on the same day. Viral titer analysis
was performed as previously described (Ludigs et al., 2016).
Engrafted Tumors
The colon adenocarcinoma cell line MC38 was grown in monolayer in DMEM
supplemented with 10% fetal calf serum (FCS), 100 U/mL of penicillin, and
100 mg/mL of streptomycin. Tumor cells were harvested with 0.05% trypsin,
washed, and resuspended inPBS for injection. 53105 tumor cellswere injected
subcutaneously (s.c.) in the flank. Tumor volume was calculated using the for-
mula V = (L3 l2)/2, where L is thewidest diameter and l is the smallest diameter.
Animalswere sacrificedwhen tumor volume reached 1,000mm3. Depending on
the experiment, starting 5–7 days post-tumor engraftment, when tumors were
palpable, mice were treated intraperitoneally with a-PD-1 (RMP1–RMP14,
BioXcell) or isotype control (2A3, BioXcell). The treatment was repeated two
times at an interval of 3–4 days for a total of three injections of 200 mg/mouse.
Statistical Analysis
Statistical analyses were performed using Prism software (GraphPad v.5.0).
Student’s t test (unpaired, two-tailed) was used to compare differences
between experimental groups. Differences were considered significant
when *p < 0.05, very significant when **p < 0.01, and highly significant when
***p < 0.001. For survival, comparisons are by log-rank (Mantel-Cox) test.
Study Approval
Mouse studies were approved by the Veterinary Office regulations of the State
of Vaud, Switzerland.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at https://doi.org/
10.1016/j.celrep.2018.03.026.
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